Skip to content

Virtual Reality Software to Reduce Stress in Cancer Patients

Feasibility Study of Virtual Reality Software to Reduce Stress in Cancer Patients Receiving Radiation Therapy

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05263648
Acronym
OU-SCC VR
Enrollment
0
Registered
2022-03-02
Start date
2023-09-30
Completion date
2025-09-30
Last updated
2024-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Head and Neck Cancer

Keywords

Virtual Reality, Radiation Therapy, Education, Distress, Stress

Brief summary

The purpose of this study is to test the ability of virtual reality-based social support to increase patient adherence to radiation therapy by reducing patient distress.

Detailed description

This study will involve patients who have been diagnosed with breast or head and neck cancer and are suitable to receive radiation therapy. It is a single arm pilot trial designed to provide information on the safety, feasibility, and impacts of incorporating virtual reality (VR) software into the treatment plan of patients receiving radiation therapy with the goal of increasing patient adherence to radiation therapy. Patients will be provided with VR-based education sessions prior to and during the course of radiation therapy. Patients' emotional and social distress levels will be assessed with questionnaires to measure the impacts of the VR software. Patients will be in the study for up to 3 months during regular cancer care, but the total time for the study procedures is anticipated to be 2-4 hours in total. Results from this study will be for research only and will not impact treatment decisions.

Interventions

VR-based education sessions will be used to influence patients' perceived emotional and social distress while undergoing radiation therapy (RT). Emotional and social distress levels will be evaluated using questionnaires at baseline (prior to the first VR experience), at completion of RT, and at 30-60 days post RT.

Sponsors

University of Oklahoma
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 years old 2. Must be able to read and speak English 3. Diagnosis of breast or head and neck cancer 4. Treatment plan includes radiotherapy within the next 2 months 5. Signed study-specific informed consent prior to study entry

Exclusion criteria

1. Previous radiation therapy treatment 2. Neurologic deficits 3. Visual disorder 4. Neuro-psychiatric disorder 5. Use of neuro-psychiatric drugs

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients who complete 2 VR sessionsUp to 3 MonthsPercentage of patients who complete 2 VR sessions will be calculated.
Proportion of patients reporting ease of use for VR sessionsUp to 3 MonthsPatients will be given a survey on their VR sessions to measure the ease of use and ability to provide useful information.
Proportion of overall adherence to radiation therapyUp to 3 MonthsPatient adherence to radiation treatment will be recorded and proportion of overall adherence will be calculated.

Secondary

MeasureTime frameDescription
Change in state trait anxiety scaleUp to 3 MonthsChange in state trait anxiety scale from baseline to follow-up will be calculated
Change in brief symptom inventoryUp to 3 MonthsChange in brief symptom inventory scale from baseline to follow-up will be calculated
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank v2.0 - Social Isolation - Short Form 8a (SI)Up to 3 MonthsChange in PROMIS Item Bank v2.0 - Social Isolation - Short Form 8a (SI) from baseline to follow-up will be calculated

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026